$MLEC

Moolec Science SA

CIK:0001937737|SEC Filings

Consolidated Statement of Comprehensive Income - USD ($)	12 Months Ended
	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2023
Profit or loss [abstract]
Revenues from contracts with customers	$ 333,611,248	$ 466,376,330	$ 420,867,429
Government grants	3,412	197,519	93,509
Initial recognition and changes in the fair value of biological assets at the point of harvest	1,764,863	(45,746)	610,554
Cost of sales	(203,424,872)	(279,368,328)	(235,464,072)
Changes in the net realizable value of agricultural products after harvest	(1,541,204)	(2,385,069)	(4,351,433)
Research and development expenses	(15,138,510)	(17,422,487)	(15,943,987)
Selling, general and administrative expenses	(125,908,240)	(126,340,822)	(116,531,274)
Share of profit or loss of joint ventures and associates	(36,927,610)	(21,023,150)	47,709,605
Other income or expenses, net	(56,589,216)	(703,265)	1,055,299
Operating (loss) profit	(104,150,129)	19,284,982	98,045,630
Financial cost	(41,809,445)	(37,634,153)	(33,576,632)
Other financial results	(24,043,905)	(9,608,981)	(13,674,756)
(Loss) Profit before income tax	(170,003,479)	(27,958,152)	50,794,242
Income tax	(6,636,121)	(1,103,152)	2,328,366
(Loss) Profit for the year	(176,639,600)	(29,061,304)	53,122,608
Items that may be subsequently reclassified to profit and loss	(3,680,709)	(1,092,833)	(911,896)
Equity holders of the parent	(114,009,391)	(32,875,350)	39,068,323
Foreign exchange differences on translation of foreign operations from joint ventures	(802,200)	977,482	(46,541)
Non-controlling interests	(66,310,918)	2,721,213	11,675,040
Foreign exchange differences on translation of foreign operations	(2,878,509)	(2,070,315)	(865,355)
Total comprehensive (loss)	(180,320,309)	(30,154,137)	50,743,363
Items that will not be subsequently reclassified to loss and profit			(1,467,349)
Revaluation of property, plant and equipment, net of tax, of joint ventures and associates			(184,630)
Revaluation of property, plant and equipment, net of tax			(1,282,719)
Total comprehensive (loss) profit	(180,320,309)	(30,154,137)	50,743,363
(Loss) / profit for the year attributable to:
Equity holders of the parent	(111,460,708)	(32,685,398)	40,435,923
Non-controlling interests	(65,178,892)	3,624,094	12,686,685
(Loss) Profit for the year	$ (176,639,600)	$ (29,061,304)	$ 53,122,608
(Loss) /Profit per share
Basic (loss) / profit attributable to ordinary equity holders of the parent (in Dollars per share)	$ (17.2461)	$ (5.6146)	$ 8.8034
Diluted (loss) / profit attributable to ordinary equity holders of the parent (in Dollars per share)	$ (17.2461)	$ (5.6146)	$ 8.8034
Total comprehensive (loss) / income attributable to:
Items that may be subsequently reclassified to profit and loss	$ (3,680,709)	$ (1,092,833)	$ (911,896)
Equity holders of the parent	(114,009,391)	(32,875,350)	39,068,323
Foreign exchange differences on translation of foreign operations from joint ventures	(802,200)	977,482	(46,541)
Non-controlling interests	(66,310,918)	2,721,213	11,675,040
Foreign exchange differences on translation of foreign operations	(2,878,509)	(2,070,315)	(865,355)
Total comprehensive (loss)	(180,320,309)	(30,154,137)	50,743,363
Items that will not be subsequently reclassified to loss and profit			(1,467,349)
Revaluation of property, plant and equipment, net of tax, of joint ventures and associates			(184,630)
Revaluation of property, plant and equipment, net of tax			(1,282,719)
Total comprehensive (loss) profit	$ (180,320,309)	$ (30,154,137)	$ 50,743,363

Consolidated Statement of Cash Flows - USD ($)

12 Months Ended

Jun. 30, 2025

Jun. 30, 2024

Jun. 30, 2023

OPERATING ACTIVITIES

(Loss) / profit for the year

$ (176,639,600)

$ (29,061,304)

$ 53,122,608

Adjustments to reconcile (loss) / profit to net cash flows

Income tax

6,636,121

1,103,152

(2,328,366)

Depreciation of property, plant and equipment

6,015,700

5,799,998

4,938,927

Amortization of intangible assets

11,201,048

12,113,223

11,004,584

Depreciation of leased assets

5,036,703

3,418,956

3,565,894

Gain from a bargain purchase

(1,473,482)

Remeasurement of previously held interest

1,666,680

Share-based incentive and stock options

4,386,688

14,199,480

3,480,178

Share of profit or loss of joint ventures and associates

36,927,610

21,023,150

(47,709,605)

Provisions for contingencies

336,919

653,574

239,292

Allowance for impairment of trade debtors

7,123,716

753,428

1,327,385

Allowance for obsolescence

1,547,723

586,515

1,066,777

Initial recognition and changes in the fair value of biological assets

(1,764,863)

45,746

(610,554)

Changes in the net realizable value of agricultural products after harvest

1,541,204

2,385,069

4,351,433

Financial results

65,853,350

47,243,134

(47,251,388)

Gain on sale of equipment and intangible assets

(7,649,848)

^[1]

(125,464)

Working capital adjustments

Trade receivables

26,040,164

(41,256,269)

(14,179,711)

Other receivables

2,039,034

(6,338,099)

(36,705,492)

Inventories and biological assets

34,880,985

15,285,866

(8,572,529)

Trade and other payables

(18,847,998)

16,286,414

14,172,818

Employee benefits and social security

(1,089,185)

(2,413,413)

2,074,795

Government grants

(3,157)

(188,518)

(93,091)

Income tax paid

(853,299)

(4,072,347)

Deferred revenue and advances from customers

(129,099)

(21,103,777)

21,019,535

Net cash flows generated by / (used in) operating activities

3,636,413

39,557,562

(41,158,857)

INVESTMENT ACTIVITIES

Proceeds from sale of property, plant and equipment

390,381

336,726

137,357

Investment in joint ventures and associates

1,085,676

Net cash received from business combination

554,420

37,508

4,373,265

Loss of controlling interest

(32,695,079)

(18,097)

(1,081,808)

Proceeds from financial assets

21,731,347

62,836,432

1,316,980

Investment in financial assets

(11,351,880)

(65,567,062)

(8,488,144)

Purchase of property, plant and equipment

(5,651,506)

(9,936,611)

(11,491,899)

Capitalized development expenditures

(8,614,448)

(11,855,766)

(10,753,047)

Purchase of intangible assets

(350,843)

(3,233,316)

(688,287)

Net cash flows used in investing activities

(35,987,608)

(27,400,186)

(25,589,907)

FINANCING ACTIVITIES

Proceeds from borrowings

403,333,190

187,994,310

150,631,747

Repayment of borrowings and financed payments

(380,033,708)

(145,044,508)

(38,457,281)

Interest payments

(28,088,688)

(36,803,697)

(25,639,013)

Leased assets payments

(5,501,387)

(4,879,108)

(3,855,517)

Cash dividend distributed by non-controlling interest

(72,051)

(174,800)

(452,129)

Other financial payments

(3,731,493)

(1,850,252)

(3,007,154)

Purchase of own shares

(926,899)

(734,388)

(2,996,947)

Net cash flows (used in) / generated by financing activities

(15,021,036)

(1,492,443)

76,223,706

Net increase / (decrease) in cash and cash equivalents

(47,372,231)

10,664,933

9,474,942

Inflation effects on cash and cash equivalents

(3,352)

(189,309)

(195,181)

Cash and cash equivalents as of beginning of the year

52,994,865

49,265,020

34,851,505

Effect of exchange rate changes on cash and equivalents

(4,851,363)

(6,745,779)

5,133,754

Cash and cash equivalents as of the end of the year

$ 767,919

$ 52,994,865

$ 49,265,020

[1]

On March 28, 2025, BIOX, a former subsidiary, agreed to transfer all rights, licenses, and materials containing or pertaining to the Soy ANF trait and pay $750,000 to a Arcadia Biosciences Inc in exchange for (i) RG and OX Wheat Patents and RS exclusive rights; (ii) the cancellation of all Royalty Payments, which included 25% of the Net Wheat Technology Licensing Revenues and 6% of the Net HB4 Soybean Revenues up to $10 million; and (iii) the release from any Performance Benchmark Obligations related to the RG, OX, and RS Varieties which amounted to $8.1 million. This transaction resulted in the accounting of a gain from the exchange of intangible assets amounting to $7.5 million.

Consolidated Statement of Financial Position - USD ($)	Jun. 30, 2025	Jun. 30, 2024
NON-CURRENT ASSETS
Other financial assets		$ 190,517
Other receivables	664,493	27,887,034
Recoverable income tax		10,889
Deferred tax assets		14,476,230
Investments in joint ventures and associates	94,147,971	92,795,851
Property, plant and equipment	3,345,170	74,612,434
Investment properties		560,783
Intangible assets	75,258,790	177,331,280
Goodwill		112,163,432
Right of use asset	100,896	11,601,752
Total non-current assets	173,517,320	511,630,202
CURRENT ASSETS
Cash and cash equivalents	767,919	52,994,865
Other financial assets	8,254,261	14,667,607
Trade receivables	6,085,400	209,007,195
Other receivables	13,849,164	34,657,383
Recoverable income tax		655,691
Inventories	2,235,482	125,929,768
Biological assets		294,134
Total current assets	31,192,226	438,206,643
Total assets	204,709,546	949,836,845
SHAREHOLDERS’ DEFICIT / EQUITY
Issued capital	1,089,176	598,369
Shared to be issued	77,589
Shares premium	39,668,135	(5,516,907)
Own shares held	(422,146)	(444,473)
Stock options and share based incentives	7,271,881	6,222,175
Retained earnings / (deficit)	(110,317,946)	1,142,761
Revaluation of property, plant and equipment reserve	(1,323,916)	(1,323,916)
Foreign currency translation reserve	(2,013,856)	534,827
Shareholders’ deficit / Equity attributable to owners of the parent	(65,971,083)	1,212,836
Non-controlling interest	(16,902,519)	248,788,534
Total shareholders’ deficit / Equity	(82,873,602)	250,001,370
NON-CURRENT LIABILITIES
Borrowings	1,348,173	127,248,305
Deferred revenue and advances from customers		1,925,138
Government grants		782
Joint ventures and associates		296,455
Deferred tax liabilities	15,767,275	34,500,445
Provisions	16,154,574	17,484,715
Consideration for acquisition		2,005,143
Convertible and non-convertible notes	18,260,456	80,809,686
Lease liabilities		8,161,359
Total non-current liabilities	51,530,478	272,432,028
CURRENT LIABILITIES
Trade and other payables	7,323,933	168,937,536
Borrowings	227,154,007	234,510,751
Employee benefits and social security	243,634	7,506,831
Deferred revenue and advances from customers	1,260	3,924,801
Income tax payable		4,825,271
Government grants	1,280	3,655
Warrant liabilities	1,211,093
Consideration for acquisition		4,571,824
Lease liabilities	117,463	3,122,778
Total current liabilities	236,052,670	427,403,447
Total liabilities	287,583,148	699,835,475
Total shareholders’ deficit / equity and liabilities	$ 204,709,546	$ 949,836,845